Why can you hurt when an image looks mild?

Why can my X-ray and soreness disagree?

Wear may be clear on an X-ray, yet the X-ray can't measure your soreness. Some joints look quite worn and cause little trouble. Others look mildly worn but ache often.

During an exam, the doctor checks how the joint moves, where it's tender, and whether it's swollen. The doctor also asks what you can no longer do with ease. Those findings add meaning to the X-ray.

Cartilage forms a smooth layer over each bone end inside the joint. Bone, tendons, muscles, and the joint lining may hurt as well. That's why the X-ray can't settle everything.

How can I tell whether care is helping?

Choose one daily task that the soreness has made hard. You might time a short walk, notice the stairs, or record whether the ache wakes you. Keep the check simple.

Try the task again after rest, gentle exercise, or a few days with less activity. Write down what you finished and how sore the joint felt. You'll have clear facts for a visit. The change may be small and still matter.

Give the joint time, and don't force a task that sharply raises the ache. Easy movement may be enough when the soreness is mild. If it isn't, QC Kinetix can discuss regenerative choices—non-surgical care intended to help the joint repair itself—after clinic staff examine the sore area and hear what movement has become hard.

Sources

1. The RESTORE trial - a participant-, injector- and assessor-blinded RCT of 288 adults aged 50+ with symptomatic medial knee OA (Kellgren-Lawrence 2-3) - compared three weekly intra-articular PRP injections against saline placebo, with co-primary endpoints of 12-month knee pain and medial tibial cartilage volume on MRI. PRP did not beat placebo on either. It is the single best-designed test of the specific claim that PRP changes joint structure, and it was negative.

   Bennell KL, et al. — Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.. JAMA, 2021. DOI: 10.1001/jama.2021.19415.

2. A 2026 systematic review and meta-analysis of 28 randomized trials of intra-articular mesenchymal stem cell-based therapies in knee OA found significant improvements in several pain and function measures (delta-VAS MD -1.67; KOOS pain MD 15.37) but NO significant difference in WOMAC, KOOS quality of life or the Lequesne index, and MRI-based WORMS scores were non-significant - indicating no consistent structural benefit. Its own conclusion: these therapies serve a primarily SYMPTOM-modifying rather than STRUCTURE-modifying role, with higher frequencies of local reactions to weigh against the symptomatic benefit.

   Awad G, et al. — Efficacy and safety of intra-articular mesenchymal stem cell-based therapies in knee osteoarthritis: A systematic review and meta-analysis of randomized controlled trials.. Clinical rheumatology, 2026. DOI: 10.1007/s10067-026-08042-w.

3. FORWARD, the longest disease-modifying osteoarthritis drug trial reported to date, gave intra-articular sprifermin (a recombinant FGF-18) or placebo to knee OA patients and followed 378 of them for 5 years. Sprifermin produced a significant, sustained dose-response INCREASE in total femorotibial cartilage thickness versus placebo - and WOMAC pain improved about 50% from baseline in ALL groups, including placebo. It is the cleanest demonstration in the literature that adding measurable cartilage and relieving pain are two different results, and that one does not deliver the other.

   Eckstein F, et al. — Long-term structural and symptomatic effects of intra-articular sprifermin in patients with knee osteoarthritis: 5-year results from the FORWARD study.. Annals of the rheumatic diseases, 2021. DOI: 10.1136/annrheumdis-2020-219181.

4. A GRADE-rated systematic review and meta-analysis of 16 randomized trials (807 participants) found that MSC therapy for chronic knee OA pain PROBABLY RESULTS IN LITTLE TO NO DIFFERENCE in pain relief at 3-6 months (WMD -0.74 cm on a 10 cm VAS against a minimally important difference of 1.5 cm) or physical functioning (WMD 2.23 on the SF-36 100-point subscale against a 10-point MID), both moderate certainty; at 12 months pain was again probably little-to-no-different (WMD -0.73 cm). The measured effect is real but sits BELOW the threshold at which a patient would notice it.

   Sadeghirad B, et al. — Mesenchymal stem cells for chronic knee pain secondary to osteoarthritis: A systematic review and meta-analysis of randomized trials.. Osteoarthritis and cartilage, 2024. DOI: 10.1016/j.joca.2024.04.021.

5. A systematic review of the discordance between clinical and radiographic knee osteoarthritis: many people with severe-looking x-rays have little pain, and many with disabling pain have modest radiographic change. This is the reason a post-treatment scan is a poor proxy for how someone feels, in either direction.

   Bedson J, et al. — The discordance between clinical and radiographic knee osteoarthritis: a systematic search and summary of the literature.. BMC musculoskeletal disorders, 2008. DOI: 10.1186/1471-2474-9-116.

6. The AAOS clinical practice guideline summary on SURGICAL management of knee osteoarthritis - the other end of the ladder, and the honest comparator for anyone told a biologic injection will let them avoid an operation.

   Srivastava AK, et al. — American Academy of Orthopaedic Surgeons Clinical Practice Guideline Summary of Surgical Management of Osteoarthritis of the Knee.. The Journal of the American Academy of Orthopaedic Surgeons, 2023. DOI: 10.5435/JAAOS-D-23-00338.